As insulin can also activate an inflammation response at higher concentrations, most likely as a negative feedback mechanism to avoid excessive energy utilization (Tsatsoulis et al., 2013; Maldonado-Ruiz et al., 2017), the dosing of insulin and the state of insulin de-sensitization in the AD patients will be crucial to determine the outcome of insulin treatment. This evidence concerns the gene INS and Alzheimer disease.